Key facts
- This page summarizes Cam Gallagher's Form 4 filing for Opus Genetics, Inc. (IRD).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Mar 2025, 16:08.
Cam Gallagher - 24 Mar 2025 Form 4 Insider Report for Opus Genetics, Inc. (IRD)
- Reporting relationship
- Director
- Issuer ticker
- IRD
- Reported as of
- 24 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Mar 2025, 16:08:12 UTC
- Prior SEC filing
- 13 Jun 2024
- Next SEC filing
- 02 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sharon Goldbach, by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cam Gallagher filed Form 4 for Opus Genetics, Inc. (IRD) on 26 Mar 2025.
Change
- Previous filing in this sequence was filed on 13 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IRD
transaction
Common Stock
Award
- Transaction value
- Shares
- +784,314
- Change %
- +1018%
- Price
- Shares after
- 861,361
- Date
- 24 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IRD
transaction
Derivative
Warrants (right to buy)
Award
- Transaction value
- Shares
- +784,314
- Change %
- Price
- Shares after
- 784,314
- Date
- 24 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 784,314
- Exercise price
- $1.15
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275.
Footnote F2
These warrants are immediately exercisable and may be called by the Issuer at any time starting with 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's common stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.